Fatal staphylococcal sepsis in Crohn's disease after infliximab

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 655-656

  Herrlinger, Klaus R ^a   Borutta, Annette ^a   Meinhardt, Gabriel ^a   Stange, Eduard F ^a   Fellermann, Klaus ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Crohn's disease; Infliximab; Sepsis

Indexed keywords

C REACTIVE PROTEIN; CLARITHROMYCIN; IMIPENEM; INFLIXIMAB; MESALAZINE; MOXIFLOXACIN; VANCOMYCIN;

ACIDOSIS; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANAMNESIS; ANUS FISTULA; ARTERIAL GAS; ARTICLE; AUTOPSY; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL FEATURE; COLON STENOSIS; COLON ULCER; COLONOSCOPY; CROHN DISEASE; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INFUSION; EXTRACORPOREAL OXYGENATION; FATALITY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERVENTILATION; HYPOXEMIA; KIDNEY FAILURE; LABORATORY TEST; LEUKOPENIA; LUNG ABSCESS; LUNG INFILTRATE; PRIORITY JOURNAL; RESPIRATORY FAILURE; STAPHYLOCOCCUS AUREUS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FATAL OUTCOME; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; PNEUMONIA, BACTERIAL; RECTAL FISTULA; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; STAPHYLOCOCCAL INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4644329257     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00024     Document Type: Article

References (20)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029-1035.
2. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
4. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-324.
5. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
6. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167:1279-1282.
7. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099-1100.
8. Andus T, Stange EF, Hoffler D, et al. [Suspected cases of severe side effects after infliximab (Remicade) in Germany] Med Klin. 2003;98:429-436.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
10. Colombel JF, Loftus E, Tremaine WJ, et al. The safety profile of infliximab for Crohn's disease in clinical practice: The Mayo Clinic experience in 500 patients. Gastroenterology 2003; 124.
11. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
12. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol. 2000;164:2016-2020.
13. Fratazzi C, Arbeit RD, Carini C, et al. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol. 1997;158: 4320-4327.
14. Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab. Am J Med. 2002;113:615.
15. Vonkeman HE, van der Valk PD, Mulder L, et al. [Fatal miliary tuberculosis during treatment with infliximab] Ned Tijdschr Geneeskd. 2002;146: 1196-1199.
16. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988;56:2563-2569.
17. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46:2255-2257.
18. Schelenz S, Smith DA, Bancroft G.J. Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-alpha and GM-CSF in neutrophil recruitment. Med Mycol. 1999;37:183-194.
19. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
20. Stange EF, Schreiber S, Folsch UR, et al. [Diagnostics and treatment of Crohn's disease - results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases] Z Gastroenterol. 2003;41:19-20.